[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"femoroacetabular-impingement\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:femoroacetabular-impingement":205},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,45,70,96,137,159,184],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100625440","arthroscopic-treatment-of-acetabular-labral-lesions-intrarticular-injection-of-bone-marrow-vs-hip-arthroscopy-alone-100625440",false,"NCT07422662","Arthroscopic Treatment of Acetabular Labral Lesions: Intrarticular Injection of Bone Marrow vs Hip Arthroscopy Alone","Single-blind Randomized Study on the Arthroscopic Treatment of Acetabular Labral Lesions: Intrarticular Injection of Bone Marrow vs Hip Arthroscopy Alone","Inclusion Criteria:\n\n1. Male or female patients aged between 18 and 55;\n2. Pelvic and hip X-ray showing no severe osteoarthritis (defined as advanced osteoarthritis with large osteophytes, chronic fractures or bone remodeling, severe deformity or bone friction, and\u002For bone-to-bone contact indicative of severe osteoarthritis\u002Fcomplete loss of cartilage);\n3. MRI of the pelvis showing suspected acetabular labral tear;\n4. Ability and consent of patients to actively participate in the rehabilitation protocol and clinical follow-up;\n5. Signature of informed consent.\n\nExclusion Criteria:\n\n1. Patients incapable of understanding and willing;\n2. Diagnosis of leukemia, known presence of metastatic malignant cells, ongoing or planned chemotherapy;\n3. Diagnosis of rheumatoid arthritis, Reiter's syndrome, psoriatic arthritis, gout, ankylosing spondylitis, or arthritis resulting from another inflammatory disease; human immunodeficiency virus (HIV) infection, viral hepatitis; chondrocalcinosis;\n4. Patients with uncontrolled diabetes mellitus;\n5. Patients with uncontrolled thyroid metabolic disorders;\n6. Patients who abuse alcohol, drugs, or medications;\n7. Body Mass Index \\> 40;\n8. Pregnancy or breastfeeding, or intention to become pregnant during the study period.\n9. Patients with a history of trauma or intra-articular infiltration of therapeutic substances in the 6 months prior to screening.\n10. Patients who have undergone hip surgery in the previous 12 months.","ALL","18 Years","55 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"NA","The BoneMarrowHip study is a single-blind, randomized, single-center trial. Through this study, the clinical results of patients treated during hip arthroscopy surgery with autologous bone marrow infiltration taken from the ipsilateral iliac crest will be evaluated and compared, comparing the outcomes with a group of patients undergoing the same surgical treatment but without intra-articular infiltration. All selected patients have acetabular labral tears diagnosed by MRI imaging. In addition, the study will evaluate the safety of the treatment by documenting any adverse events.",[27],"FemoroAcetabular Impingement",[29,30,31],"BMAC injection","hip arthroscopy","Acetabular labral tears","NOT_YET_RECRUITING","2026-06-30",{"date":35,"type":36},"2026-07-01","ACTUAL",{"date":38,"type":21},"2026-09",{"date":40,"type":21},"2032-04",{"name":42,"class":43},"Istituto Ortopedico Rizzoli","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":44},"100496615","an-evaluation-of-hip-preservation-outcomes-100496615","NCT05746533","An Evaluation of Hip Preservation Outcomes","A Comparison of Total Hip Arthroplasty and Hip Preservation Outcomes","Inclusion Criteria:\n\n* Candidates for surgical intervention of the hip\n* Participant and\u002For guardian has given informed consent and assent as applicable.\n\nExclusion Criteria:\n\n* Documented history of pre-existing hip conditions (SCFE, LCPD, acetabular fractures)\n* Has language or cognitive barriers preventing understanding of study and consent and assent documents\n* Prior revision surgeries\n* Patients from the trauma\u002Femergency department\n* Individuals with Unusable x-rays","12 Years",{"count":54,"type":21},10000,"OBSERVATIONAL","The purpose of this study is to assess outcomes of hip preservation surgeries including open and arthroscopic treatment of femoroacetabular impingement (FAI).",[58,59],"Hip Arthroscopy","Femoroacetabular Impingement","RECRUITING","2026-05-15",{"date":63,"type":36},"2026-05-19",{"date":65,"type":36},"2023-06-02",{"date":67,"type":21},"2053-06",{"name":69,"class":43},"Yale University",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":78,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":44},"100537012","biomechanical-investigation-of-symptomatic-fai-and-two-groups-of-asymptomatic-controls-100537012","NCT06272292","Biomechanical Investigation of Symptomatic FAI and Two Groups of Asymptomatic Controls","An Integrated Biomechanical Investigation of Subjects With Symptomatic FAI and Two Groups of Asymptomatic Controls: a Comparison in Dynamic Tasks","CAM-FAI adult","Exclusion Criteria:\n\n\\- Participants in all three study groups will be excluded if x-ray scans shows a pincer FAI morphology or radiological sign of osteoarthritis.\n\nInclusion Criteria:\n\n* All participants will be males aged between 21 and 35 years old.\n* For symptomatic CAM-FAI patients\n\n  1. The presence of CAM-FAI morphology at the head-neck junction of the femur\n  2. Alpha angle \\>60\n  3. Reduced hip internal rotation (IR\\\u003C15)\n* For asymptomatic CAM controls:\n\n  1\\. Exhibit asymptomatic CAM on x-ray scansAlpha angle \\>60\n* For Healthy control group:\n\n  1. Exhibit no symptoms or abnormal morphologies of the proximal femur (Alpha angle \\>60 , IR\\>15).",true,"MALE","21 Years","35 Years",{"count":83,"type":21},99,[24],"Femoroacetabular impingement (FAI) is an orthopaedic condition that is primarily characterized by the presence of anatomic bony abnormalities in the femoral head and\u002For the acetabulum resulting in an abnormal contact between the two during hip motion, especially in positions of increased hip flexion and rotation, ultimately leading to hip pain. Unfortunately, a FAI diagnosis is frequently only made once symptoms have become severe to an extent that they limit everyday life activities. Moreover, another important aspect that has been consistently overlooked in past FAI movement studies is the influence muscle strength and activation can have on movement pattern and symptom presentation. The diagnosis and management of FAI needs to be addressed through a more wholesome investigation of the biomechanical influence on the manifestation of symptoms.\n\nThis project aims to further unravel the link between spinopelvic anatomy, its biomechanical contribution to femoro-pelvic motion and the manifestation of femoroacetabular impingement in adult male population. By, for the first time, integrating three-dimensional (3D) instrumented motion analysis with state-of-the-art full-body biplanar X-ray imaging (EOS imaging, Paris France), we will more specifically investigate the presence of an association between spinopelvic kinematics and the link to symptomatic FAI morphology, as well as investigate the presence of differences in these measures between symptomatic and asymptomatic subjects with comparable femoral morphology.",[59],"2026-03-12",{"date":89,"type":36},"2026-03-16",{"date":91,"type":36},"2022-07-28",{"date":93,"type":21},"2026-12-31",{"name":95,"class":43},"Universitaire Ziekenhuizen KU Leuven",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":102,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":107,"conditions":108,"keywords":114,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":44},"100579345","early-feasibility-study-of-cartilage-defect-repair-100579345","NCT06823089","Early Feasibility Study of Cartilage Defect Repair","Inclusion Criteria:\n\n1. At least 14 years of age to no older than 64 years of age Subjects 14-21 years of age must have radiographic evidence of epiphyseal closure in the hip joint\n2. BMI \\\u003C 35\n3. Failed at least 6 weeks of conservative treatment (e.g., anti-inflammatory pain medications, physical therapy, injections)\n4. Duration of symptoms consistent with intra-articular disease (i.e., groin, lateral and\u002For posterior hip pain) that have persisted for at least 3 months)\n5. Loss of articular cartilage integrity (\\~1 - 6 cm\\^2 in area) on the femoral head (confirmed by MRI), without an opposing lesion, that can be treated with a single ReNew Hip Implant\n6. Radiographic assessment with joint space width \\> 2 mm (verified by x-ray)\n7. Meets an acceptable preoperative medical clearance and is free of conditions that would pose excessive operative risk, in the opinion of the investigator\n8. Given consent to participate in the study\n9. Able to understand the purpose of the study, his\u002Fher role, and is available for follow-up for the duration of the study:\n\n   1. Subject has signed an IRB (Institutional Review Board) approved Informed Consent Form agreeing to participate in the extension study after the nature, scope, and possible consequences of the study have been explained in an understandable form\n   2. Subject is able to fully understand the purpose of the study, his\u002Fher role as a participant in the study, and plans to be available through five years post-operative follow-up\n\nExclusion Criteria:\n\n1. Current users of nicotine in any form (e.g., cigarettes, e- cigarettes\u002Fvaping, chewing tobacco, nicotine patches, gum, lozenges), or individuals who have discontinued nicotine use less than 30 days prior to screening.\n2. Type 1 or Type 2 Diabetes\n3. Systemic steroid use in the 3 months prior to screening\n4. Coxa plana, coxa magna, or proximal femoral focal deficiency on the femoral head that would result in implant mismatch of the femoral head contour\n5. Any acute or chronic condition that would limit the ability of the patient to participate in the study (e.g., COPD, congestive heart failure),\n6. Bleeding disorders\n7. Current cancer (with the exception of non-melanoma skin cancer)\n8. Pregnancy or planning to become pregnant during the study period\n9. Active infection or sepsis\n10. History of local hip infection\n11. Known metastatic or neoplastic disease\n12. Conditions that may interfere with implant survival or outcomes (e.g., severe dysplasia)\n13. Life expectancy less than 2 years\n14. Intra-articular therapy within 3 months of enrollment\n15. Inadequate bone stock (as determined by SCORE or MORES assessment) to support the device\n16. Femoral head is:\n\n    1. outside of the 46 - 56 mm range in either anteroposterior diameter or lateral diameters or\n    2. an aspherical head deformity that results in contour mismatch of 16a\n17. Moderate to severe renal insufficiency\n18. Emotional or neurological condition that would preempt ability or willingness to participate in the study\n19. Above the knee amputation of the contralateral or ipsilateral leg\n20. Known allergies to the components of the device (polycaprolactone)\n21. Is a prisoner","14 Years","64 Years",{"count":105,"type":21},15,[24],"Any patient aged 14 or older up to 64 years of age with hip disease, resulting in loss of articular cartilage integrity on the femoral head (e.g., femoroacetabular impingement or other structural deformity), has failed conservative care, and is a candidate for surgical intervention to treat.",[109,59,110,111,112,113],"Osteoarthritis, Hip","Osteonecrosis","Legg-Calvé-Perthes Disease","Osteochondral Lesion","Hip Dysplasia",[115,116,117,118,119,120,121,122,123,124,125,126,127],"articular cartilage","hip resurfacing","residual Perthes disease","post-Perthes deformity","femoral head deformity","secondary hip osteoarthritis","hip preservation surgery","adolescent hip deformity","adult hip deformity","avascular necrosis of femoral head","early-stage avascular necrosis","Perthes sequelae","traumatic femoral head lesion","2026-02-12",{"date":130,"type":36},"2026-02-17",{"date":132,"type":36},"2025-11-06",{"date":134,"type":21},"2031-10",{"name":136,"class":43},"Cytex Therapeutics, Inc.",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":22,"phases":146,"briefSummary":147,"conditions":148,"keywords":149,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":157,"locationsCount":44},"100613798","3d-mri-assessment-of-femoroacetabular-impingement-in-patients-with-acl-rupture---exploratory-study-100613798","NCT07271277","3D MRI Assessment of Femoroacetabular Impingement in Patients With ACL Rupture - Exploratory Study","IMAHANCHE","Inclusion Criteria:\n\n* Patient, male or female, aged 18 years or older\n* Patient with a primary complete ACL rupture\n* Patient affiliated with or covered by a social security scheme\n* Patient who speaks French and has signed an informed consent form\n\nExclusion Criteria:\n\n* Patient with multi-ligament injury\n* Patients with a history of hip fracture\n* Patients with a history of hip surgery\n* Patients with a contraindication to MRI\n* Protected individuals: adults under guardianship, curatorship or other legal protection, deprived of their liberty by judicial or administrative decision\n* Pregnant or breastfeeding women",{"count":145,"type":21},50,[24],"Anterior cruciate ligament (ACL) tears are among the most common sports injuries. Numerous studies have shown that reduced hip rotation may play a role in ACL tears. The same question may also arise for hip injuries such as femoroacetabular impingement (FAI).\n\nThis research is based on the hypothesis that there is a relationship between FAI and ACL injury. In this context, 3D MRI of the hip would provide morphological details of the hip that are not currently available with other imaging techniques, thereby enabling early identification of FAI. This is the reason why this research has been initiated.",[59],[150],"femoroacetabular impingement","2025-11-27",{"date":153,"type":36},"2025-12-09",{"date":155,"type":21},"2026-01-01",{"date":93,"type":21},{"name":158,"class":43},"GCS Ramsay Santé pour l'Enseignement et la Recherche",{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":16,"minAge":165,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":22,"phases":167,"briefSummary":169,"conditions":170,"keywords":172,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":4},"100573782","phase-4-intraoperative-bone-marrow-aspirate-concentrate-injections-evaluating-outcomes-in-a-randomized-controlled-trial-100573782","NCT06750757","Intraoperative Bone Marrow Aspirate Concentrate Injections: Evaluating Outcomes in a Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients undergoing primary hip arthroscopy to treat femoroacetabular impingement\n* Subjects will require a clinical diagnosis of intra-articular pathology consisting of anterior hip and\u002For groin pain with restricted hip motion and positive impingement testing.\n* Study inclusion also requires the radiographic hallmarks of Cam type femoroacetabular impingement with an alpha angle greater than 60 degrees on Dunn lateral views and advanced imaging with magnetic resonance imaging (MRI) or magnetic resonance arthrography (MRA) confirming chondrolabral pathology.\n\nExclusion Criteria:\n\n* Patients who have had prior hip arthroscopy or hip surgery, Tonnis grade II or higher radiographic osteoarthritis, congenital hip deformities including Legg-Calve-Perthes or Slipped Capital Femoral Epiphysis, rheumatologic conditions, or workers compensation claims.\n* Patients undergoing additional arthroscopic procedures such as trochanteric bursectomy or gluteus medius repair will also be excluded.","16 Years",{"count":20,"type":21},[168],"PHASE4","The purpose of this study is to see if bone marrow aspirate concentrate (BMAC) used with your hip arthroscopy surgery is a better treatment than just having surgery alone for treatment of labral tears in your hip.\n\nBMAC is an injection, where your doctor will insert a needle into your hip and harvest the bone marrow that is located inside of your bones. This will be performed under anesthesia during your hip arthroscopy surgery and will be injected during the procedure. BMAC is an FDA approved procedure and has had many research articles produced from it.\n\nResearchers will compare patients who received BMAC during their surgery to those who have not to determine if the injection with surgery is better than surgery alone.",[171,59],"Labral Tear",[30,173,174],"bone marrow aspirate concentrate","orthobiologics","2024-12-20",{"date":177,"type":36},"2024-12-27",{"date":179,"type":21},"2025-02",{"date":181,"type":21},"2028-02",{"name":183,"class":43},"American Hip Institute",{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":191,"enrollmentInfo":192,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":194,"conditions":195,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":44},"100557282","the-relationship-between-gait-and-severity-of-femoroacetabular-impingement-100557282","NCT06536088","The Relationship Between Gait and Severity of Femoroacetabular Impingement","The Relationship Between Spatiotemporal Gait Parameters and Imaging-based Characteristics of Femoroacetabular Impingement (FAI) in Symptomatic Individuals","Inclusion Criteria:\n\n* Patients with femoroacetabular impingement scheduled for hip arthroscopy\n\nExclusion Criteria:\n\n* Severe hip osteoarthritis\n* Hip dysplasia\n* Previous ipsilateral and\u002For contralateral hip surgery,\n* Any orthopedic or neurologic pathology that may affect gait patterns","75 Years",{"count":193,"type":21},25,"In this study, the spatiotemporal gait parameters of symptomatic femoroacetabular impingement (FAI) patients scheduled for hip arthroscopy are evaluated. Radiological measurements, including the Alpha angle (AA), Lateral Center-Edge Angle (LCEA), and Kellgren-Lawrence (KL) osteoarthritis classification, are recorded from patient files. The relationship between these radiological measurements and walking parameters is assessed. Additionally, the spatiotemporal gait parameters of FAI patients are compared with those of a healthy control group.\n\nWalking assessments provide valuable insights into how Femoroacetabular Impingement (FAI) affects movement and aid in evaluating treatment outcomes. Research indicates that individuals with FAI experience reduced hip motion and slower walking speeds. By analyzing spatiotemporal gait parameters-such as gait velocity, cadence, step length, and vertical center of mass-the impact of FAI on walking can be better understood, leading to the development of targeted treatment strategies. The goal is to explore the correlation between these gait parameters and imaging-based FAI characteristics in affected individuals.",[59],"2024-07-31",{"date":198,"type":36},"2024-08-02",{"date":200,"type":36},"2022-01-01",{"date":202,"type":21},"2024-12-30",{"name":204,"class":43},"Gazi University","Femoroacetabular, Impingement"]